share: digg facebook twitter Disappointing results were reported Thursday for a large study looking at whether a bone-strengthening drug added to standard breast cancer treatment lowered the risk that the disease would return. [...] AZURE, a larger British study of 3,360 breast cancer patients, found no overall benefit to adding the drug to standard treatments, said Dr. Robert Coleman, professor ...